The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor bulk as a prognostic biomarker and predictor of benefit from anti-EGFR therapy in patients with metastatic colorectal cancer: Analysis of 476 patients from the ARCAD Clinical Trials Program.
 
Benjamin Adam Weinberg
Honoraria - Onclive; Rafael Pharmaceuticals; Tempus
Consulting or Advisory Role - Bayer
Speakers' Bureau - Bayer; HalioDx; Lilly; Sirtex Medical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Ipsen (Inst); Isofol Medical (Inst); Novartis (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Boehringer Ingelheim; Caris Life Sciences
 
Manel Rakez
No Relationships to Disclose
 
Benoist Chibaudel
Honoraria - Bayer; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - BeiGene; Roche; Sanofi; SERVIER
Travel, Accommodations, Expenses - Merck; MSD; Roche; Sanofi
 
Tim Maughan
No Relationships to Disclose
 
Richard Adams
Honoraria - Amgen; Merck Serono; SERVIER
Consulting or Advisory Role - Amgen; Merck Serono; SERVIER
Speakers' Bureau - Merck Serono
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; SERVIER
 
John Raymond Zalcberg
Stock and Other Ownership Interests - Acceleron Pharma; Aimmune; Alnylam; Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Global Blood Therapeutics; GW Pharmaceuticals; Madrigal Pharmaceuticals; Moderna Therapeutics; Myovant Sciences; Opthea; Orphazyme; Sangamo Bioscience; UniQure; Vertex; Zogenix
Honoraria - Gilead Sciences; Halozyme; Merck Serono; Novella Clinical; pfizer; Specialised Therapeutics; Targovax
Consulting or Advisory Role - Center for Emerging & Neglected Diseases (CEND); Halozyme; Lipotek; Merck Serono; Merck Sharp & Dohme; Pfizer; Sirtex Medical; Specialised Therapeutics; Targovax
Research Funding - AstraZeneca (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Specialised Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Merck Serono; Merck Sharp & Dohme
 
Axel Grothey
Honoraria - Aptitude Health; Elsevier; IMEDEX
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech/Roche; Lilly (Inst); OBI Pharma
Research Funding - Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bayer; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche
 
Takayuki Yoshino
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Qian Shi
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Merck
Consulting or Advisory Role - Boehringer Ingelheim; Yiviva
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
 
Aimery De Gramont
No Relationships to Disclose
 
Dustin A. Deming
Consulting or Advisory Role - Acrotech Biopharma; Array BioPharma; Bayer; Novocure; Pfizer; Promega
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Millennium (Inst); Revolution Medicines (Inst)